{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:25:23Z","timestamp":1778657123183,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Eckenstein-Geigy foundation"},{"name":"Adjuvare Foundation"},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["IZJFZ3_185646"],"award-info":[{"award-number":["IZJFZ3_185646"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["IZJFZ3_185646"],"award-info":[{"award-number":["IZJFZ3_185646"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40262-021-01048-4","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T01:02:40Z","timestamp":1627002160000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen"],"prefix":"10.1007","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct04056325","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-9248","authenticated-orcid":false,"given":"Cornelis","family":"Smit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somphou","family":"Sayasone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-1228","authenticated-orcid":false,"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"e2288","DOI":"10.1371\/journal.pntd.0002288","volume":"7","author":"F Sch\u00e4r","year":"2013","unstructured":"Sch\u00e4r F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis. 2013;7:e2288.","journal-title":"PLoS Negl Trop Dis"},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"e2165","DOI":"10.1371\/journal.pntd.0002165","volume":"7","author":"AJ Krolewiecki","year":"2013","unstructured":"Krolewiecki AJ, Lammie P, Jacobson J, Gabrielli A-F, Levecke B, Socias E, et al. A public health response against Strongyloides stercoralis: time to look at soil-transmitted helminthiasis in full. PLoS Negl Trop Dis. 2013;7:e2165.","journal-title":"PLoS Negl Trop Dis"},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.trstmh.2009.02.013","volume":"103","author":"A Olsen","year":"2009","unstructured":"Olsen A, van Lieshout L, Marti H, Polderman T, Polman K, Steinmann P, et al. Strongyloidiasis\u2013the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg. 2009;103:967\u201372.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.trstmh.2011.08.013","volume":"105","author":"A-F Gabrielli","year":"2011","unstructured":"Gabrielli A-F, Montresor A, Chitsulo L, Engels D, Savioli L. Preventive chemotherapy in human helminthiasis: theoretical and operational aspects. Trans R Soc Trop Med Hyg. 2011;105:683\u201393.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1048_CR5","first-page":"CD007745","volume":"1","author":"C Henriquez-Camacho","year":"2016","unstructured":"Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC, Terashima A, Samalvides F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane database Syst Rev. 2016;1:CD007745.","journal-title":"Cochrane database Syst Rev"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0304-4017(94)00743-V","volume":"59","author":"WL Shoop","year":"1995","unstructured":"Shoop WL, Mrozik H, Fisher MH. Structure and activity of avermectins and milbemycins in animal health. Vet Parasitol. 1995;59:139\u201356.","journal-title":"Vet Parasitol"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","volume":"392","author":"NO Opoku","year":"2018","unstructured":"Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392:1207\u201316.","journal-title":"Lancet"},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1371\/journal.pntd.0002953","volume":"8","author":"K Awadzi","year":"2014","unstructured":"Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8:e953.","journal-title":"PLoS Negl Trop Dis"},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1177\/0091270003257456","volume":"43","author":"MM Cotreau","year":"2003","unstructured":"Cotreau MM, Warren S, Ryan JL, Fleckenstein L, Vanapalli SR, Brown KR, et al. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol. 2003;43:1108\u201315.","journal-title":"J Clin Pharmacol"},{"key":"1048_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30691-5","author":"D Hofmann","year":"2021","unstructured":"Hofmann D, Sayasone S, Sengngam K, Chongvilay B, Hattendorf J, Keiser J. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S1473-3099(20)30691-5 (Epub 30 Mar 2021).","journal-title":"Lancet Infect Dis"},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/2160763X11432508","volume":"1","author":"JM Korth-Bradley","year":"2012","unstructured":"Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin. Clin Pharmacol Drug Dev. 2012;1:32\u20137.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/cpdd.81","volume":"3","author":"JM Korth-Bradley","year":"2014","unstructured":"Korth-Bradley JM, Parks V, Wagner F, Chalon S, Gourley I, Matschke K, et al. Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. Clin Pharmacol Drug Dev. 2014;3:151\u20137.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1048_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/cts.12583","volume":"11","author":"SA Kinrade","year":"2018","unstructured":"Kinrade SA, Mason JW, Sanabria CR, Rayner CR, Bullock JM, Stanworth SH, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci. 2018;11:582\u20139.","journal-title":"Clin Transl Sci"},{"key":"1048_CR14","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.1128\/AAC.00311-11","volume":"55","author":"JM Korth-Bradley","year":"2011","unstructured":"Korth-Bradley JM, Parks V, Chalon S, Gourley I, Matschke K, Gossart S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother. 2011;55:5200\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1021\/jf960981s","volume":"45","author":"J Afzal","year":"1997","unstructured":"Afzal J, Burke AB, Batten PL, DeLay RL, Miller P. Moxidectin: metabolic fate and blood pharmacokinetics of 14C-labeled moxidectin in horses. J Agric Food Chem. 1997;45:3627\u201333.","journal-title":"J Agric Food Chem"},{"key":"1048_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1021\/jf00038a028","volume":"42","author":"J Zulalian","year":"1994","unstructured":"Zulalian J, Stout SJ, DaCunha AR, Garces T, Miller P. Absorption, tissue distribution, metabolism, and excretion of moxidectin in cattle. J Agric Food Chem. 1994;42:381\u20137.","journal-title":"J Agric Food Chem"},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejps.2006.10.004","volume":"30","author":"A Lespine","year":"2007","unstructured":"Lespine A, Martin S, Dupuy J, Roulet A, Pineau T, Orlowski S, et al. Interaction of macrocyclic lactones with P-glycoprotein: Structure-affinity relationship. Eur J Pharm Sci. 2007;30:84\u201394.","journal-title":"Eur J Pharm Sci"},{"key":"1048_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00228-010-0851-0","volume":"66","author":"KA Oshikoya","year":"2010","unstructured":"Oshikoya KA, Sammons HM, Choonara I. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 2010;66:1025\u201335.","journal-title":"Eur J Clin Pharmacol"},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpara.2009.11.001","volume":"40","author":"TG Geary","year":"2010","unstructured":"Geary TG, Woo K, McCarthy JS, Mackenzie CD, Horton J, Prichard RK, et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol. 2010;40:1\u201313.","journal-title":"Int J Parasitol"},{"key":"1048_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122556","author":"D Hofmann","year":"2021","unstructured":"Hofmann D, Sayasone S, Keiser J. Development and validation of an LC-MS\/MS method for the quantification of the anthelmintic drug moxidectin in a volumetric absorptive microsample, blood, and plasma: application to a pharmacokinetic study of adults infected with S. stercoralis. J Chromatogr B Anal Technol Biomed Life Sci. 2021. https:\/\/doi.org\/10.1016\/j.jchromb.2021.122556 (Epub 1 Mar 2021).","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1048_CR21","unstructured":"Lixoft SAS. Monolix suite version 2019R2. 2019. https:\/\/www.lixoft.com\/products\/monolix\/."},{"key":"1048_CR22","unstructured":"R Core Team. R: A language and environment for statistical computing. 2019. https:\/\/www.r-project.org\/."},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.12793\/tcp.2019.27.2.73","volume":"27","author":"H Cho","year":"2019","unstructured":"Cho H, Lee E-K. PKconverter: R package to convert the pharmacokinetic parameters. Transl Clin Pharmacol. 2019;27:73\u20139.","journal-title":"Transl Clin Pharmacol."},{"key":"1048_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cpt.1456","volume":"106","author":"JM Brussee","year":"2019","unstructured":"Brussee JM, Schulz JD, Coulibaly JT, Keiser J, Pfister M. Ivermectin dosing strategy to achieve equivalent exposure coverage in children and adults. Clin Pharmacol Ther. 2019;106:661\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1048_CR28","first-page":"e00714","volume":"65","author":"JM Brussee","year":"2021","unstructured":"Brussee JM, Neodo A, Schulz JD, Coulibaly JT, Pfister M, Keiser J. Pharmacometric analysis of tribendimidine mono- and combination therapies to achieve high cure rates in patients with hookworm infections. Antimicrob Agents Chemother. 2021;65(2):e00714-e720.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1048_CR29","first-page":"e01778","volume":"65","author":"JM Brussee","year":"2021","unstructured":"Brussee JM, Hiroshige N, Neodo A, Coulibaly JT, Pfister M, Keiser J. Population pharmacokinetics and exposure-response analysis of tribendimidine to improve treatment for children with hookworm infection. Antimicrob Agents Chemother. 2021;65(2):e01778-e1820.","journal-title":"Antimicrob Agents Chemother"},{"key":"1048_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00436-004-1084-x","volume":"93","author":"A Lespine","year":"2004","unstructured":"Lespine A, Sutra JF, Dupuy J, Alvinerie M, Aumont G. The influence of parasitism on the pharmacokinetics of moxidectin in lambs. Parasitol Res. 2004;93:121\u20136.","journal-title":"Parasitol Res"},{"key":"1048_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s002280050131","volume":"50","author":"OZ Baraka","year":"1996","unstructured":"Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MMA, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407\u201310.","journal-title":"Eur J Clin Pharmacol"},{"key":"1048_CR32","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/jphp.13154","volume":"71","author":"JH Hughes","year":"2019","unstructured":"Hughes JH, Upton RN, Reuter SE, Phelps MA, Foster DJR. Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. J Pharm Pharmacol. 2019;71:1635\u201344.","journal-title":"J Pharm Pharmacol"},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/j.1552-4604.1983.tb02750.x","volume":"23","author":"DR Abernethy","year":"1983","unstructured":"Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983;23:369\u201376.","journal-title":"J Clin Pharmacol"},{"key":"1048_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","volume":"14","author":"C Smit","year":"2018","unstructured":"Smit C, De Hoogd S, Br\u00fcggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14:275\u201385.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1048_CR35","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40262-015-0298-7","volume":"54","author":"F Rodieux","year":"2015","unstructured":"Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet. 2015;54:1183\u2013204.","journal-title":"Clin Pharmacokinet"},{"key":"1048_CR36","unstructured":"Medicines Development for Global Health. Moxidectin package insert. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210867Orig1s000TOC.cfm"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01048-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T17:16:23Z","timestamp":1642353383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01048-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01048-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"5 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided by Universit\u00e4t Basel (Universit\u00e4tsbibliothek Basel). Marc Pfister and Cornelis Smit are financially supported by the Eckenstein\u2010Geigy Foundation in Basel, Switzerland. Jennifer Keiser and Daniela Hofmann are financially supported by the Adjuvare Foundation and the Swiss National Science Foundation (No. IZJFZ3_185646).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marc Pfister has part\u2010time employment with the consulting company Certara LP (USA). Cornelis Smit, Daniela Hofmann, Somphou Sayasone, and Jennifer Keiser declare no competing interests for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Ethical clearance was obtained from the National Ethics Committee for Health Research on 12 September 2019 in Laos (reference no. 082-NECHR) and the Ethics Committee of Northwestern and Central Switzerland on 15 July 2019 (no. 2019-00558). This study was conducted in full accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice, and is registered at ClinicalTrials.gov (identifier: NCT04056325).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study protocol for this publication is available on ClinicalTrials.gov (NCT04056325). Individual de-identified participant data that underlie the results reported in this article are available upon request, beginning directly after publication and ending 1 year after. Access will be granted to researchers who provide a scientifically sound proposal. Requests should be directed to Jennifer Keiser (jennifer.keiser@swisstph.ch). Data requestors will be required to sign a data access agreement prior to access being granted.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The MLXTRAN code for the final PK model is provided in the Electronic Supplementary File.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}